Antibody Blockade of the PSGL-1 Immune Checkpoint Enhances T Cell Responses to B-Cell Lymphoma

The authors investigated the potential of PSGL-1 antibody targeting in B-cell lymphoma. Using allogeneic co-culture systems, they demonstrated that targeted antibody interventions against human PSGL-1 enhanced T cell activation and effector cytokine production in response to lymphoma cells.